Co-Authors
This is a "connection" page, showing publications co-authored by LUIS E FAYAD and DAVID SANGHYUN HONG.
Connection Strength
0.402
-
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018 11 16; 6(1):119.
Score: 0.164
-
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18; 7(314):314ra185.
Score: 0.133
-
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv. 2023 11 14; 7(21):6785-6789.
Score: 0.058
-
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587.
Score: 0.047